Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD
LEXINGTON, Mass., March 21, 2022 /PRNewswire/ — Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced positive…
Comments Off on Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD